Medication-induced osteonecrosis of the maxilla, potentiated by fungical infection: Case report DOI Creative Commons
Gabriel Cunha Collini, Bianca de Fátima Borim Pulino, Guilherme Cunha Collini

et al.

E-Acadêmica, Journal Year: 2023, Volume and Issue: 4(1), P. e0441404 - e0441404

Published: Jan. 6, 2023

Osteonecrosis of the jaws induced using bisphosphonates refers to a condition characterized by exposure necrotic bone, usually in face region and commonly originating from trauma. has its highest prevalence mandible may be initially manifested ulcerations oral mucosa, which expose underlying bone due poor vascularization use bisphosphonates. Bisphosphonates are indicated for treatment several comorbidities, such as malignant tumors, metastases, osteoporosis. Actinomycosis is rarely pathological concern low virulence organism, but it can manifest itself when associated with other pathologies osteonecrosis. The clinical case presents patient who made prolonged low-intensity trauma evolving maxillary osteonecrosis potentiated actnomyses. This article aims demonstrate connection between actinomycosis chronic importance correct diagnosis treatment.

Language: Английский

BISPHOSPHONATE–RELATED OSTEONECROSIS OF THE JAW A 3-YEARS RETROSPECTIVE STUDY OF FREQUENCY AND RISK FACTORS DOI Creative Commons
Росен Цолов, Elena Firkova, Ivan Chenchev

et al.

Journal of IMAB - Annual Proceeding (Scientific Papers), Journal Year: 2019, Volume and Issue: 25(3), P. 2617 - 2621

Published: July 22, 2019

Purpose: To estimate the frequency of bisphosphonate-related osteonecrosis (BRONJ) in Bulgarian population between 2015-2018 and correlation with type bisphosphonates as risk factors associated BRONJ development.Materials methods: A retrospective analysis official database from national health insurance system was conducted.The total number patients developed estimated.The intravenous bisphosphonate administered incidence BRONJ.Results: 3543 during 2015 -2018.The condition is constantly increasing.The among receiving ibandronate acid significantly higher than on alendronic treatment (p <0.001).Conclusions: increasing cancer patients, treated bisphosphonates.Administration Ibandronic can be used a significant factor predictor for development those patients.

Language: Английский

Citations

6
Medication-Induced Osteonecrosis of the Jaw: A Review of Cases from the Food and Drug Administration Adverse Event Reporting System (FAERS) DOI Creative Commons
Hardeep Ahdi,

Thomas A. Wichelmann,

Sasirekha Pandravada

et al.

Research Square (Research Square), Journal Year: 2022, Volume and Issue: unknown

Published: May 17, 2022

Abstract Introduction: Osteonecrosis of the jaw (ONJ) is a rare but serious adverse drug reaction (ADR) commonly associated with bisphosphonate and denosumab therapy. Prior research utilized an online, public FDA Adverse Event Reporting System (FAERS) Database to explore this ADR. This data identified described several novel medications ONJ. Our study aims build upon prior findings, reporting trends medication induced ONJ over time identifying newly medications. Methods: We searched FAERS database for all reported cases related osteonecrosis (MRONJ) from 2010 2021. Cases lacking patient age or gender were excluded. Only adults (18+) reports Healthcare Professions included. Duplicate removed. The top 20 April 2010-December 2014 2015-January Results: 19,668 2010-2021. 8,908 met inclusion criteria. 3,132 2010-2014 5,776 2015-2021. Within 2010-2014, 64.7% female 35.3% male, average was 66.1+/-11.1 years. Between 2015-2021, 64.3% 35.7% 69.2+/-11.5 Review classes not previously described. They include lenalidomide, corticosteroids (prednisolone dexamethasone), docetaxel paclitaxel, letrozole, methothrexate, imatinib, teriparatide. Novel drugs between 2015-2021 palbociclib, pomalidomide, radium 223, nivolumab, cabozantinib. Discussion: While stricter criteria removal duplicate led fewer overall MRONJ when compared research, our represents more reliable analysis database. Denosumab most frequently unable imply incidence rates due nature database, findings provide further description various elucidate demographics Additionally, identifies that have been in literature.

Language: Английский

Citations

2
Medication Related Osteonecrosis of Jaw: A Medical Oncologist’s Perspective DOI Creative Commons

Harry S Darling

Journal of Dental and Maxillofacial Surgery, Journal Year: 2018, Volume and Issue: 1(1), P. 10 - 17

Published: Feb. 14, 2018

Medication related osteonecrosis of jaw (MRONJ) is a rare iatrogenic disease. Cancer therapeutics advancing exponentially and apart from major emphasis on quality life (QoL) in metastatic patients, now we are foreseeing increased longevity. This necessitates the rising need betterment supportive care modalities looking into complications therapy. Bisphosphonates (BPs) Denosumab, anti-resorptive agents (ARAs) used commonly by medical oncologists cancers with bone metastases less prevention or treatment osteoporosis, implicated etiology MRONJ. Many times, it goes undetected, underdiagnosed untreated due to lack awareness, low index suspicion paucity understanding this disorder amongst oncology fraternity. A high cornerstone timely diagnosis therapeutic action. regular collaboration between treating oncologist dentist utmost importance.

Language: Английский

Citations

1
The Importance of Dental Screening Prior to Commencing Anti-Resorptive Therapy for Treatment of Cancer: A Case Report and Discussion DOI

Fiona McDonnell,

Clare Steel,

Fiona McDonnell

et al.

Primary Dental Journal, Journal Year: 2018, Volume and Issue: 7(3), P. 42 - 45

Published: Sept. 1, 2018

Osteonecrosis of the jaws (ONJ) can be a serious complication radiation and anti-resorptive therapies. At present, patients due to undergo radiotherapy are required have dental assessment treat current or anticipated disease prior commencing treatment. However no agreed guidelines in place for those start therapy cancer. More now being treated with various drug therapies new combinations drugs unknown long-term effects, many surviving their longer periods time. It is important increase awareness among professionals possibility them developing medication-related osteonecrosis jaw (MRONJ) put effective preventative measures help stop such complications developing. Case Report A 52-year-old patient complex medical history, including metastatic breast cancer, presented generalised oral pain tooth mobility (see Figure 1). The developed extensive stage III MRONJ following concurrent use multiple treatment secondary bone disease. Dental consisted provision antibiotics, hydrogen peroxide chlorhexidine mouthwashes extraction symptomatic teeth bony sequestra. Conclusion Once established, challenging manage both team patient. This case demonstrates importance comprehensive examination need starting order prevent instances.

Language: Английский

Citations

1
Medication-induced osteonecrosis of the maxilla, potentiated by fungical infection: Case report DOI Creative Commons
Gabriel Cunha Collini, Bianca de Fátima Borim Pulino, Guilherme Cunha Collini

et al.

E-Acadêmica, Journal Year: 2023, Volume and Issue: 4(1), P. e0441404 - e0441404

Published: Jan. 6, 2023

Osteonecrosis of the jaws induced using bisphosphonates refers to a condition characterized by exposure necrotic bone, usually in face region and commonly originating from trauma. has its highest prevalence mandible may be initially manifested ulcerations oral mucosa, which expose underlying bone due poor vascularization use bisphosphonates. Bisphosphonates are indicated for treatment several comorbidities, such as malignant tumors, metastases, osteoporosis. Actinomycosis is rarely pathological concern low virulence organism, but it can manifest itself when associated with other pathologies osteonecrosis. The clinical case presents patient who made prolonged low-intensity trauma evolving maxillary osteonecrosis potentiated actnomyses. This article aims demonstrate connection between actinomycosis chronic importance correct diagnosis treatment.

Language: Английский

Citations

0